We are live on ! Find out more
EIM

Essex Investment Management Portfolio holdings

AUM $632M
1-Year Est. Return 95.36%
This Fund
S&P 500
This Quarter Est. Return
+31.23%
1 Year Est. Return
+95.36%
3 Year Est. Return
+271.62%
5 Year Est. Return
+354.98%
10 Year Est. Return
+3,586.14%
AUM
$550M
AUM Growth
+$70.6M
Cap. Flow
-$37M
Cap. Flow %
-6.73%
Top 10 Hldgs %
19.32%
Holding
327
New
24
Increased
23
Reduced
152
Closed
29

Top Buys

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$5.02M
2
GEV icon
GE Vernova
GEV
+$2.92M
3
COHU icon
Cohu
COHU
+$2.47M
4
MAMA icon
Mama's Creations
MAMA
+$2.39M
5
ORN icon
Orion Group Holdings
ORN
+$2.25M

Sector Composition

Rank Sector Weight
1 Industrials 30.33%
2 Technology 26.01%
3 Healthcare 18.4%
4 Financials 6.04%
5 Consumer Staples 4.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PG icon
126
Procter & Gamble
PG
$335B
$1.51M 0.27%
9,452
HVT icon
127
Haverty Furniture Companies
HVT
$441M
$1.49M 0.27%
+73,200
New +$1.43M
XYL icon
128
Xylem
XYL
$28.5B
$1.44M 0.26%
11,134
-298
-3% -$36.1K
BLND icon
129
Blend Labs
BLND
$331M
$1.36M 0.25%
413,549
-2,952
-0.7% -$10K
AXP icon
130
American Express
AXP
$232B
$1.3M 0.24%
4,089
INVE icon
131
Identive
INVE
$63.4M
$1.3M 0.24%
399,133
-2,883
-0.7% -$9.26K
TRMB icon
132
Trimble
TRMB
$13.1B
$1.29M 0.23%
16,993
-7,792
-31% -$523K
VMI icon
133
Valmont Industries
VMI
$9.52B
$1.27M 0.23%
3,877
-4,083
-51% -$1.25M
XPRO icon
134
Expro Ltd
XPRO
$2.07B
$1.25M 0.23%
145,949
-1,000
-0.7% -$8.49K
AJG icon
135
Arthur J. Gallagher & Co
AJG
$65.5B
$1.24M 0.23%
3,887
EYPT icon
136
EyePoint Inc
EYPT
$1.17B
$1.16M 0.21%
123,691
-892
-0.7% -$6.16K
SG icon
137
Sweetgreen
SG
$693M
$1.13M 0.21%
76,002
-521
-0.7% -$8.59K
WMS icon
138
Advanced Drainage Systems
WMS
$10.6B
$1.11M 0.2%
9,624
-4,362
-31% -$489K
CGNX icon
139
Cognex
CGNX
$10.2B
$1.08M 0.2%
34,023
+6,233
+22% +$179K
CL icon
140
Colgate-Palmolive
CL
$73.6B
$1.03M 0.19%
11,382
APD icon
141
Air Products & Chemicals
APD
$67.7B
$1.01M 0.18%
3,576
-473
-12% -$129K
VLTO icon
142
Veralto
VLTO
$23.6B
$937K 0.17%
9,281
-4,206
-31% -$406K
MRSH
143
Marsh
MRSH
$90.1B
$860K 0.16%
3,933
JPM icon
144
JPMorgan Chase
JPM
$971B
$847K 0.15%
2,923
VLO icon
145
Valero Energy
VLO
$95.1B
$847K 0.15%
6,302
MP icon
146
MP Materials
MP
$9.64B
$823K 0.15%
24,748
-50,011
-67% -$1.28M
NPCE icon
147
Neuropace
NPCE
$500M
$821K 0.15%
73,659
-64,767
-47% -$810K
MTSI icon
148
MACOM Technology Solutions
MTSI
$23.7B
$774K 0.14%
5,400
DE icon
149
Deere & Co
DE
$167B
$740K 0.13%
1,455
-651
-31% -$319K
MLM icon
150
Martin Marietta Materials
MLM
$32.7B
$732K 0.13%
1,333
-72
-5% -$38.1K

Similar funds

Essex Investment Management's Q2 2025 Portfolio in Review

As of Q2 2025, Essex Investment Management held 327 positions worth $550M, up 15% from $479M the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Essex Investment Management withdrew a net $37M in Q2 2025, closing 29 positions and reducing 152 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $6.56M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 30% of assets, up from 25% a quarter earlier, followed by Technology and Healthcare.

Against the trend, Essex Investment Management opened a new position in Mirum Pharmaceuticals worth $5.74M.

  • Essex Investment Management's largest Q2 2025 buy was Mirum Pharmaceuticals: 112,731 shares worth $5.74M.
  • Essex Investment Management added most to GE Vernova in Q2 2025, an estimated $2.92M increase.
  • Essex Investment Management's biggest Q2 2025 reduction was Nutex Health, cutting an estimated $7.08M.
  • Essex Investment Management fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $6.56M.
  • Essex Investment Management's ten largest holdings make up 19% of its $550M portfolio in Q2 2025.
  • Essex Investment Management opened 24 new positions and closed 29 in Q2 2025.
  • Essex Investment Management's portfolio value rose 15% quarter-over-quarter to $550M.

Based on Essex Investment Management's 13F filing for Q2 2025, filed 12 Aug 2025.